Natco Pharma Limited (NSE: NATCOPHARM.NS) Stock Competitors & Peer Comparison

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SUNPHARMA.NS has a market cap of 4.7T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SUNPHARMA.NS trades at ₹1,941.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SUNPHARMA.NS's P/E ratio is 37.71. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUNPHARMA.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SUNPHARMA.BO has a market cap of 4.7T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SUNPHARMA.BO trades at ₹1,941.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SUNPHARMA.BO's P/E ratio is 38.06. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUNPHARMA.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, DIVISLAB.NS has a market cap of 1.9T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while DIVISLAB.NS trades at ₹7,248.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas DIVISLAB.NS's P/E ratio is 74.64. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to DIVISLAB.NS's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DIVISLAB.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, DIVISLAB.BO has a market cap of 1.9T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while DIVISLAB.BO trades at ₹7,246.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas DIVISLAB.BO's P/E ratio is 71.63. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to DIVISLAB.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DIVISLAB.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, TORNTPHARM.NS has a market cap of 1.7T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while TORNTPHARM.NS trades at ₹4,961.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas TORNTPHARM.NS's P/E ratio is 74.34. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to TORNTPHARM.NS's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to TORNTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check TORNTPHARM.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, TORNTPHARM.BO has a market cap of 1.7T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while TORNTPHARM.BO trades at ₹4,959.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas TORNTPHARM.BO's P/E ratio is 75.26. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to TORNTPHARM.BO's ROE of +0.26%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to TORNTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check TORNTPHARM.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ZYDUSLIFE.NS trades at ₹1,108.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ZYDUSLIFE.NS's P/E ratio is 23.04. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ZYDUSLIFE.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ZYDUSLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ZYDUSLIFE.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ZYDUSLIFE.BO trades at ₹1,108.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ZYDUSLIFE.BO's P/E ratio is 23.13. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ZYDUSLIFE.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ZYDUSLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ZYDUSLIFE.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while LUPIN.BO trades at ₹2,369.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas LUPIN.BO's P/E ratio is 18.60. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to LUPIN.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LUPIN.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while LUPIN.NS trades at ₹2,370.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas LUPIN.NS's P/E ratio is 18.61. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to LUPIN.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LUPIN.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, MANKIND.NS has a market cap of 1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while MANKIND.NS trades at ₹2,507.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas MANKIND.NS's P/E ratio is 50.75. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to MANKIND.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to MANKIND.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check MANKIND.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, MANKIND.BO has a market cap of 1T. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while MANKIND.BO trades at ₹2,505.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas MANKIND.BO's P/E ratio is 51.05. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to MANKIND.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to MANKIND.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check MANKIND.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, DRREDDY.NS has a market cap of 971.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while DRREDDY.NS trades at ₹1,151.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas DRREDDY.NS's P/E ratio is 22.68. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to DRREDDY.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to DRREDDY.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DRREDDY.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, DRREDDY.BO has a market cap of 971.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while DRREDDY.BO trades at ₹1,152.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas DRREDDY.BO's P/E ratio is 22.68. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to DRREDDY.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to DRREDDY.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check DRREDDY.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AUROPHARMA.NS has a market cap of 881.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AUROPHARMA.NS trades at ₹1,532.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AUROPHARMA.NS's P/E ratio is 25.39. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AUROPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AUROPHARMA.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AUROPHARMA.BO has a market cap of 880.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AUROPHARMA.BO trades at ₹1,531.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AUROPHARMA.BO's P/E ratio is 25.38. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AUROPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AUROPHARMA.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, LAURUSLABS.NS has a market cap of 865B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while LAURUSLABS.NS trades at ₹1,601.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas LAURUSLABS.NS's P/E ratio is 97.28. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to LAURUSLABS.NS's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to LAURUSLABS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LAURUSLABS.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, LAURUSLABS.BO has a market cap of 865B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while LAURUSLABS.BO trades at ₹1,602.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas LAURUSLABS.BO's P/E ratio is 96.93. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to LAURUSLABS.BO's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to LAURUSLABS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check LAURUSLABS.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ALKEM.BO has a market cap of 673.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ALKEM.BO trades at ₹5,635.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ALKEM.BO's P/E ratio is 29.26. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ALKEM.BO's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALKEM.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ALKEM.NS has a market cap of 673.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ALKEM.NS trades at ₹5,633.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ALKEM.NS's P/E ratio is 34.68. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ALKEM.NS's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALKEM.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GLENMARK.BO has a market cap of 619B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GLENMARK.BO trades at ₹2,193.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GLENMARK.BO's P/E ratio is 45.47. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLENMARK.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GLENMARK.NS has a market cap of 618.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GLENMARK.NS trades at ₹2,192.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GLENMARK.NS's P/E ratio is 35.93. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GLENMARK.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLENMARK.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, IPCALAB.BO has a market cap of 447.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while IPCALAB.BO trades at ₹1,762.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas IPCALAB.BO's P/E ratio is 49.16. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to IPCALAB.BO's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to IPCALAB.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IPCALAB.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, IPCALAB.NS has a market cap of 447.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while IPCALAB.NS trades at ₹1,762.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas IPCALAB.NS's P/E ratio is 38.10. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to IPCALAB.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to IPCALAB.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IPCALAB.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AJANTPHARM.NS has a market cap of 421B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AJANTPHARM.NS trades at ₹3,369.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AJANTPHARM.NS's P/E ratio is 39.90. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AJANTPHARM.NS's ROE of +0.25%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AJANTPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AJANTPHARM.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AJANTPHARM.BO has a market cap of 420.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AJANTPHARM.BO trades at ₹3,366.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AJANTPHARM.BO's P/E ratio is 39.87. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AJANTPHARM.BO's ROE of +0.25%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AJANTPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AJANTPHARM.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SUVENPHAR.NS's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVENPHAR.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVENPHAR.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVENPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVENPHAR.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JBCHEPHARM.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, JBCHEPHARM.BO has a market cap of 386.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas JBCHEPHARM.BO's P/E ratio is 52.61. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JBCHEPHARM.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, EMCURE.NS has a market cap of 356.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while EMCURE.NS trades at ₹1,881.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas EMCURE.NS's P/E ratio is 70.98. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to EMCURE.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check EMCURE.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, WOCKPHARMA.BO has a market cap of 299.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while WOCKPHARMA.BO trades at ₹1,842.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas WOCKPHARMA.BO's P/E ratio is 140.50. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to WOCKPHARMA.BO's ROE of +0.04%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to WOCKPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check WOCKPHARMA.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to PEL.NS's ROE of +0.01%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PEL.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, PPLPHARMA.BO has a market cap of 240.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while PPLPHARMA.BO trades at ₹181.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas PPLPHARMA.BO's P/E ratio is -154.68. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PPLPHARMA.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, PPLPHARMA.NS has a market cap of 240.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while PPLPHARMA.NS trades at ₹181.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas PPLPHARMA.NS's P/E ratio is -154.78. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PPLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PPLPHARMA.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, NEULANDLAB.BO has a market cap of 238.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while NEULANDLAB.BO trades at ₹18,570.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas NEULANDLAB.BO's P/E ratio is 64.24. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NEULANDLAB.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NEULANDLAB.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, NEULANDLAB.NS has a market cap of 237.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while NEULANDLAB.NS trades at ₹18,546.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas NEULANDLAB.NS's P/E ratio is 61.84. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NEULANDLAB.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NEULANDLAB.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GRANULES.NS has a market cap of 206.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GRANULES.NS trades at ₹833.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GRANULES.NS's P/E ratio is 33.56. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GRANULES.NS's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GRANULES.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GRANULES.BO has a market cap of 206.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GRANULES.BO trades at ₹833.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GRANULES.BO's P/E ratio is 33.55. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GRANULES.BO's ROE of +0.16%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GRANULES.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ASTRAZEN.NS has a market cap of 200.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ASTRAZEN.NS trades at ₹8,005.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ASTRAZEN.NS's P/E ratio is 106.73. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ASTRAZEN.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ASTRAZEN.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ASTRAZEN.BO has a market cap of 200.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ASTRAZEN.BO trades at ₹8,000.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ASTRAZEN.BO's P/E ratio is 106.65. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ASTRAZEN.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ASTRAZEN.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ERIS.NS has a market cap of 194.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ERIS.NS trades at ₹1,400.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ERIS.NS's P/E ratio is 39.62. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ERIS.NS's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ERIS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ERIS.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ERIS.BO has a market cap of 194B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ERIS.BO trades at ₹1,398.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ERIS.BO's P/E ratio is 45.36. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ERIS.BO's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ERIS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ERIS.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, CAPLIPOINT.NS has a market cap of 187.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while CAPLIPOINT.NS trades at ₹2,467.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas CAPLIPOINT.NS's P/E ratio is 28.99. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to CAPLIPOINT.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to CAPLIPOINT.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check CAPLIPOINT.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, CAPLIPOINT.BO has a market cap of 187.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while CAPLIPOINT.BO trades at ₹2,464.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas CAPLIPOINT.BO's P/E ratio is 32.80. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to CAPLIPOINT.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to CAPLIPOINT.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check CAPLIPOINT.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, NATCOPHARM.BO has a market cap of 164.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while NATCOPHARM.BO trades at ₹920.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas NATCOPHARM.BO's P/E ratio is 12.42. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NATCOPHARM.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, COHANCE.BO has a market cap of 159.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while COHANCE.BO trades at ₹417.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas COHANCE.BO's P/E ratio is 82.45. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to COHANCE.BO's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to COHANCE.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check COHANCE.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, COHANCE.NS has a market cap of 159.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while COHANCE.NS trades at ₹417.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas COHANCE.NS's P/E ratio is 77.60. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to COHANCE.NS's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to COHANCE.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check COHANCE.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, APLLTD.BO has a market cap of 157.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while APLLTD.BO trades at ₹796.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas APLLTD.BO's P/E ratio is 21.24. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check APLLTD.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, APLLTD.NS has a market cap of 156.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while APLLTD.NS trades at ₹797.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas APLLTD.NS's P/E ratio is 21.27. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to APLLTD.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check APLLTD.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, JUBLPHARMA.NS has a market cap of 152.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while JUBLPHARMA.NS trades at ₹965.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas JUBLPHARMA.NS's P/E ratio is 35.62. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to JUBLPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JUBLPHARMA.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, JUBLPHARMA.BO has a market cap of 152.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while JUBLPHARMA.BO trades at ₹962.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas JUBLPHARMA.BO's P/E ratio is 35.50. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to JUBLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check JUBLPHARMA.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ALIVUS.BO has a market cap of 135.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ALIVUS.BO trades at ₹1,101.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ALIVUS.BO's P/E ratio is 24.51. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ALIVUS.BO's ROE of +0.05%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ALIVUS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALIVUS.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ALIVUS.NS has a market cap of 135.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ALIVUS.NS trades at ₹1,101.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ALIVUS.NS's P/E ratio is 41.01. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ALIVUS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ALIVUS.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GLS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLS.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GLS.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GLS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GLS.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SHILPAMED.NS has a market cap of 118.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SHILPAMED.NS trades at ₹606.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SHILPAMED.NS's P/E ratio is 46.81. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SHILPAMED.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, PGHL.NS has a market cap of 111.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while PGHL.NS trades at ₹6,714.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas PGHL.NS's P/E ratio is 34.10. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to PGHL.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PGHL.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, PGHL.BO has a market cap of 111.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while PGHL.BO trades at ₹6,723.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas PGHL.BO's P/E ratio is 37.26. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, NATCOPHARM.NS is similarly volatile compared to PGHL.BO. This indicates similar risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check PGHL.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, VIYASH.NS has a market cap of 109.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while VIYASH.NS trades at ₹250.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas VIYASH.NS's P/E ratio is 77.92. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to VIYASH.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check VIYASH.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check CAPPL.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AKUMS.NS has a market cap of 105.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AKUMS.NS trades at ₹687.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AKUMS.NS's P/E ratio is 55.03. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AKUMS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AKUMS.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, STAR.NS has a market cap of 94B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while STAR.NS trades at ₹1,020.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas STAR.NS's P/E ratio is 16.92. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to STAR.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check STAR.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, STAR.BO has a market cap of 93.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while STAR.BO trades at ₹1,019.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas STAR.BO's P/E ratio is 16.90. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, NATCOPHARM.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check STAR.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SUDEEPPHRM.NS has a market cap of 93.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SUDEEPPHRM.NS trades at ₹825.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SUDEEPPHRM.NS's P/E ratio is 95.39. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUDEEPPHRM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUDEEPPHRM.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SUVEN.BO has a market cap of 71.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SUVEN.BO trades at ₹316.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SUVEN.BO's P/E ratio is -25.49. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SUVEN.BO's ROE of -0.87%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVEN.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SUVEN.NS has a market cap of 71.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SUVEN.NS trades at ₹316.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SUVEN.NS's P/E ratio is -26.20. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SUVEN.NS's ROE of -0.87%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SUVEN.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SPARC.BO has a market cap of 70.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SPARC.BO trades at ₹216.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SPARC.BO's P/E ratio is 4.52. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SPARC.BO's ROE of +14.36%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SPARC.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SPARC.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SPARC.NS has a market cap of 70.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SPARC.NS trades at ₹216.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SPARC.NS's P/E ratio is 4.52. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SPARC.NS's ROE of +14.36%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SPARC.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SPARC.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, FDC.NS has a market cap of 67.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while FDC.NS trades at ₹412.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas FDC.NS's P/E ratio is 26.76. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to FDC.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check FDC.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AARTIPHARM.NS has a market cap of 61.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AARTIPHARM.NS trades at ₹673.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AARTIPHARM.NS's P/E ratio is 23.29. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIPHARM.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AARTIPHARM.BO has a market cap of 61.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AARTIPHARM.BO trades at ₹674.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AARTIPHARM.BO's P/E ratio is 32.54. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIPHARM.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SHILPAMED.BO has a market cap of 59.2B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SHILPAMED.BO trades at ₹605.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SHILPAMED.BO's P/E ratio is 48.65. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SHILPAMED.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SHILPAMED.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, INNOVACAP.NS has a market cap of 54.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while INNOVACAP.NS trades at ₹950.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas INNOVACAP.NS's P/E ratio is 44.69. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to INNOVACAP.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check INNOVACAP.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SEQUENT.BO's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SEQUENT.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SEQUENT.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SEQUENT.NS's ROE of +0.09%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SEQUENT.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SEQUENT.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ORCHPHARMA.NS has a market cap of 50.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ORCHPHARMA.NS trades at ₹988.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ORCHPHARMA.NS's P/E ratio is 159.45. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ORCHPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ORCHPHARMA.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, ORCHPHARMA.BO has a market cap of 50.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while ORCHPHARMA.BO trades at ₹987.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas ORCHPHARMA.BO's P/E ratio is 67.66. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to ORCHPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check ORCHPHARMA.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, BLISSGVS.NS has a market cap of 49.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while BLISSGVS.NS trades at ₹464.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas BLISSGVS.NS's P/E ratio is 38.56. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to BLISSGVS.NS's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check BLISSGVS.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, BLISSGVS.BO has a market cap of 49.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while BLISSGVS.BO trades at ₹463.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas BLISSGVS.BO's P/E ratio is 38.47. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to BLISSGVS.BO's ROE of +0.11%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check BLISSGVS.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, RPGLIFE.BO has a market cap of 48.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while RPGLIFE.BO trades at ₹2,913.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas RPGLIFE.BO's P/E ratio is 41.83. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to RPGLIFE.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check RPGLIFE.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, RPGLIFE.NS has a market cap of 48.6B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while RPGLIFE.NS trades at ₹2,937.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas RPGLIFE.NS's P/E ratio is 42.17. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to RPGLIFE.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check RPGLIFE.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, IOLCP.BO has a market cap of 43.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while IOLCP.BO trades at ₹149.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas IOLCP.BO's P/E ratio is 29.29. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IOLCP.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, IOLCP.NS has a market cap of 43.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while IOLCP.NS trades at ₹149.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas IOLCP.NS's P/E ratio is 29.37. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check IOLCP.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, NOVARTIND.BO has a market cap of 40.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while NOVARTIND.BO trades at ₹1,647.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas NOVARTIND.BO's P/E ratio is 42.86. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NOVARTIND.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NOVARTIND.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, NOVARTIND.NS has a market cap of 40.1B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while NOVARTIND.NS trades at ₹1,641.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas NOVARTIND.NS's P/E ratio is 42.71. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to NOVARTIND.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check NOVARTIND.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GUJTHEM.NS has a market cap of 39.3B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GUJTHEM.NS trades at ₹360.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GUJTHEM.NS's P/E ratio is 83.84. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GUJTHEM.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GUJTHEM.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GUFICBIO.NS has a market cap of 38B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GUFICBIO.NS trades at ₹378.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GUFICBIO.NS's P/E ratio is 59.20. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GUFICBIO.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GUFICBIO.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, GUFICBIO.BO has a market cap of 38B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while GUFICBIO.BO trades at ₹378.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas GUFICBIO.BO's P/E ratio is 59.10. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to GUFICBIO.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check GUFICBIO.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, UNICHEMLAB.NS has a market cap of 37.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while UNICHEMLAB.NS trades at ₹537.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas UNICHEMLAB.NS's P/E ratio is 14.96. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to UNICHEMLAB.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check UNICHEMLAB.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, UNICHEMLAB.BO has a market cap of 37.8B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while UNICHEMLAB.BO trades at ₹539.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas UNICHEMLAB.BO's P/E ratio is 15.02. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to UNICHEMLAB.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check UNICHEMLAB.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AARTIDRUGS.NS has a market cap of 36.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AARTIDRUGS.NS trades at ₹404.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AARTIDRUGS.NS's P/E ratio is 19.04. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AARTIDRUGS.NS's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIDRUGS.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIDRUGS.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, AARTIDRUGS.BO has a market cap of 36.9B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while AARTIDRUGS.BO trades at ₹404.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas AARTIDRUGS.BO's P/E ratio is 19.04. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to AARTIDRUGS.BO's ROE of +0.13%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to AARTIDRUGS.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check AARTIDRUGS.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, MOREPENLAB.BO has a market cap of 29.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while MOREPENLAB.BO trades at ₹53.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas MOREPENLAB.BO's P/E ratio is 31.09. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to MOREPENLAB.BO's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to MOREPENLAB.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check MOREPENLAB.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, MOREPENLAB.NS has a market cap of 29.5B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while MOREPENLAB.NS trades at ₹53.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas MOREPENLAB.NS's P/E ratio is 28.62. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to MOREPENLAB.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check MOREPENLAB.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SOLARA.NS has a market cap of 23.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SOLARA.NS trades at ₹491.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SOLARA.NS's P/E ratio is 279.52. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SOLARA.NS's ROE of -0.00%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SOLARA.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SOLARA.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, SOLARA.BO has a market cap of 23.7B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while SOLARA.BO trades at ₹490.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas SOLARA.BO's P/E ratio is 357.92. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to SOLARA.BO's ROE of -0.00%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to SOLARA.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check SOLARA.BO's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, INDOCO.NS has a market cap of 22.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while INDOCO.NS trades at ₹243.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas INDOCO.NS's P/E ratio is -17.30. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to INDOCO.NS's ROE of -0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to INDOCO.NS. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check INDOCO.NS's competition here

Natco Pharma Limited (NSE: NATCOPHARM.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NATCOPHARM.NS stands at 165B. In comparison, INDOCO.BO has a market cap of 22.4B. Regarding current trading prices, NATCOPHARM.NS is priced at ₹921.45 on the NSE, while INDOCO.BO trades at ₹242.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NATCOPHARM.NS currently has a P/E ratio of 12.45, whereas INDOCO.BO's P/E ratio is -23.26. In terms of profitability, NATCOPHARM.NS's ROE is +0.17%, compared to INDOCO.BO's ROE of -0.10%. Regarding short-term risk, NATCOPHARM.NS is less volatile compared to INDOCO.BO. This indicates lower risk in terms of short-term price fluctuations for NATCOPHARM.NS.Check INDOCO.BO's competition here